Brilliant Violet 421™ anti-mouse/human CD11b Antibody

Catalog# / Size	101235 / 125 µL 101251 / 50 µg 101236 / 500 µL
Clone	M1/70
Regulatory Status	RUO
Other Names	αM integrin, Mac-1, Mo1, CR3, Ly-40, C3biR, ITGAM
Isotype	Rat IgG2b, κ
Description	CD11b is a 170 kD glycoprotein also known as αM integrin, Mac-1 α subunit, Mol, CR3, and Ly-40. CD11b is a member of the integrin family, primarily expressed on granulocytes, monocytes/macrophages, dendritic cells, NK cells, and subsets of T and B cells. CD11b non-covalently associates with CD18 (β2 integrin) to form Mac-1. Mac-1 plays an important role in cell-cell interaction by binding its ligands ICAM-1 (CD54), ICAM-2 (CD102), ICAM-4 (CD242), iC3b, and fibrinogen.

Product Details

Verified Reactivity	Mouse, Human, Cynomolgus, Rhesus
Reported Reactivity	Chimpanzee, Baboon, Rabbit
Antibody Type	Monoclonal
Host Species	Rat
Immunogen	C57BL/10 splenocytes
Formulation	Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).
Preparation	The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 421™ under optimal conditions.
Concentration	µg sizes: 0.2 mg/mL µL sizes: lot-specific (to obtain lot-specific concentration, please enter the lot number in our Concentration and Expiration Lookup or Certificate of Analysis online tools.)
Storage & Handling	The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. **Do not freeze.**
Application	FC - *Quality tested*
Recommended Usage	Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining using the µg size, the suggested use of this reagent is ≤ 0.25 µg per million cells in 100 µL volume. For flow cytometric staining using the µL sizes, the suggested use of this reagent is 5 µL per million cells in 100 µL staining volume or 5 µL per 100 µL of whole blood. It is recommended that the reagent be titrated for optimal performance for each application. Brilliant Violet 421™ excites at 405 nm and emits at 421 nm. The standard bandpass filter 450/50 nm is recommended for detection. Brilliant Violet 421™ is a trademark of Sirigen Group Ltd. Learn more about Brilliant Violet™. This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.
Excitation Laser	Violet Laser (405 nm)
Application Notes	Clone M1/70 has been verified for immunocytochemistry (ICC) and frozen immunohistochemistry

(IHC-F).

Additional reported applications (for relevant formats of this clone) include: immunoprecipitation[1,4], *in vitro* blocking[3,9,12], depletion[2,8], immunofluorescence microscopy[6,7,10], immunohistochemistry of acetone-fixed frozen sections[5,11-13], and spatial biology (IBEX)[35,36]. For *in vivo* studies or highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) (Cat. No. 101248).

Application References

1. Springer T, *et al.* 1978. *Eur. J. Immunol.* 8:539. (IP)
2. Ault K and Springer T. 1981. *J. Immunol.* 126:359. (Deplete)
3. Springer TA, *et al.* 1982. *Immunol. Rev.* 68:171. (Block)
4. Ho MK and Springer TA. 1983. *J. Biol. Chem.* 258:2766. (IP)
5. Flotte TJ, *et al.* 1983. *Am. J. Pathol.* 111:112. (IHC)
6. Noel GJ, *et al.* 1990. J. Clin. Invest. 85:208. (IF)
7. Allen LA and Aderem A. 1996. *J. Exp. Med.* 184:627 (IF)
8. D'Amico A and Wu L. 2003. *J. Exp. Med.* 198:293. (Deplete)
9. Brickson SJ, *et al.* 2003. *Appl Physiol.* 95:969. (Block)
10. Clatworthy MR and Smith KG. 2004. *J. Exp. Med.* 199:717. (IF)
11. Hata H, *et al.* 2004. *J. Clin. Invest.* 114:582. (IHC)
12. Zhang Y, *et al.* 2002. *J. Immunol.* 168:3088. (IHC)
13. Iwasaki A and Kelsall BL. 2001. *J. Immunol.* 166:4884 (IHC, FC)
14. Tailleux L. 2003. *J. Exp. Med.* 197:121. (Block, FC)
15. Olver S, *et al.* 2006. *Cancer Research* 66:571. (FC)
16. Tan SL, *et al.* 2006. *J. Immunol.* 176:2872. (FC) PubMed
17. Ponomarev ED, *et al.* 2006. *J. Immunol.* 176:1402. (FC)
18. Dzhagalov I, *et al.* 2007. *Blood* 109:1620. (FC)
19. Fazilleau N, *et al.* 2007. *Nature Immunol.* 8:753.
20. Rasmussen JW, *et al.* 2006. *Infect. Immun.*74:6590. PubMed
21. Napimoga MH, *et al.* 2008. *J. Immunol.* 180:609. PubMed
22. Elqaraz-Carmon V, *et al.* 2008. *J. Lipid. Res.* 49:1894. PubMed
23. Kim DD, *et al.* 2008. *Blood* 112:1109. PubMed
24. Guo Y, *et al.* 2008. *Blood* 112:480. PubMed
25. Norian LA, *et al.* 2009. *Cancer Res.* 69:3086. (FC) PubMed
26. Baumgartner CK, *et al.* 2010. *J. Immunol.* 184:573. PubMed
27. Charles N, *et al.* 2010. *Nat. Med.* 16:701. (FC) PubMed
28. Whiteland J, *et al.* 1995. *J. Histochem. Cytochem.* 43:313. (IHC)
29. Weber GF, *et al.* 2014. *J Exp Med.* 211:1243. PubMed
30. Ashok A, *et al.* 2015. *Toxicol Sci.* 143:64. PubMed
31. Price PJ, *et al.* 2015. *J Immunol.* 194:1164. PubMed
32. Doni A, *et al.* 2015. *J Exp Med.* 212:905. PubMed
33. Ferreira R, *et al.* 2016. J Infect Dis. 213: 669 - 673. PubMed
34. Peterson VM, *et al.* 2017. *Nat. Biotechnol.* 35:936. (PG)
35. Radtke AJ, *et al.* 2020. *Proc Natl Acad Sci U S A.* 117:33455-65. (SB) PubMed
36. Radtke AJ, *et al.* 2022. *Nat Protoc.* 17:378-401. (SB) PubMed

Product Citations

1. Doni A, *et al.* 2015. J Exp Med. 212:905. PubMed
2. Däbritz J, *et al.* 2016. Sci Rep. 6:20584. PubMed
3. Chai Y, *et al.* 2016. PLoS One. 11: 0162853. PubMed
4. Moderzynski K, *et al.* 2016. PLoS Negl Trop Dis. . PubMed
5. Hou X, *et al.* 2020. Cell Reports. 28(1):172-189.e7.. PubMed
6. Liu J, *et al.* 2019. Immunity. 50:600. PubMed
7. Ilinykh PA, *et al.* 2020. Cell Host & Microbe. 27(6):976-991. PubMed
8. Su Y, *et al.* 2022. J Hematol Oncol. 15:99. PubMed
9. Miller CM, *et al.* 2020. J Virol. 94:00:00. PubMed
10. Li Q, *et al.* 2019. Neuron. 101:207. PubMed
11. Klemm F, *et al.* 2020. Cell. 181(7):1643-1660.e17. PubMed
12. Yan L, *et al.* 2021. Front Cell Neurosci. 15:750373. PubMed
13. Acharya N, *et al.* 2020. Immunity. 53(3):658-671.e6. PubMed
14. Liu X, *et al.* 2013. Diabetes. 62:4228. PubMed
15. Chen J, *et al.* 2022. Nat Commun. 13:6759. PubMed
16. Piirsalu M, *et al.* 2022. Cells. 11:. PubMed
17. Kremenovic M, *et al.* 2022. J Immunother Cancer. 10:. PubMed
18. Ma C, *et al.* 2018. Science. 360:eaan5931. PubMed
19. Currier MA, *et al.* 2017. Oncotarget. 8:17412. PubMed
20. Joseph R, *et al.* 2021. Br J Cancer. 125:176. PubMed
21. Linnerbauer M, *et al.* 2022. Front Immunol. 12:800128. PubMed
22. McDowell SAC, *et al.* 2021. Nat Cancer. 2:545. PubMed
23. Talma N, *et al.* 2021. Aging Cell. 20:e13450. PubMed
24. Perner C, *et al.* 2020. Immunity. 53(5):1063-1077.e7. PubMed
25. Xu D *et al.* 2018. Cell. 174(6):1477-1491 . PubMed
26. Hao F, *et al.* 2021. Proc Natl Acad Sci U S A. 118:. PubMed
27. Sugita J, *et al.* 2021. Nat Commun. 12:1910. PubMed
28. Sokol CL *et al.* 2018. Immunity. 49(3):449-463 . PubMed
29. Sabbagh MF *et al.* 2018. eLife. 7 pii: e36187. PubMed
30. Yousef H, *et al.* 2018. Bio Protoc. 8:22. PubMed
31. Zirngibl F, *et al.* 2021. J Immunother Cancer. 9:. PubMed
32. Salei N, *et al.* 2020. J Am Soc Nephrol. 31:257. PubMed
33. Singh S, *et al.* 2021. Cell Host Microbe. 29(3):347-361.e12. PubMed

34. Bryson BD, *et al.* 2019. Nat Commun. 10:2329. PubMed
35. Cong J *et al.* 2018. Cell metabolism. 28(2):243-255 . PubMed
36. Mifflin L, *et al.* 2021. Proc Natl Acad Sci U S A. 118:. PubMed
37. Cassidy BR, *et al.* 2020. J Neuroinflammation. 17:259. PubMed
38. Korangath P, *et al.* 2020. Bio Protoc. 10:e3822. PubMed
39. Weber G, *et al.* 2014. J Exp Med. 211:1243. PubMed
40. Derecka M, *et al.* 2020. Nat Immunol. 261:21. PubMed
41. Ruer-Laventie J, *et al.* 2020. Bio Protoc. e3531:10. PubMed
42. Grzelak A, *et al.* 2018. Int J Mol Sci. 19:. PubMed
43. Rashidi M, *et al.* 2019. J Immunol. 203:736. PubMed
44. Alikhanyan K, *et al.* 2021. Cancers (Basel). 13:. PubMed
45. Progatzky F, *et al.* 2021. Nature. 599:125. PubMed
46. Muraleedharan A, *et al.* 2021. Glia. 69:697. PubMed
47. Knizkova D, *et al.* 2022. Nat Immunol. 23:1644. PubMed
48. Bennett M, *et al.* 2016. Proc Natl Acad Sci U S A. 113: 1738 - 1746. PubMed
49. O'Connor T, *et al.* 2020. Cancer Cell. 36(3):250-267. PubMed
50. Liakopoulos V, *et al.* 2018. Sci Rep. 8:13964. PubMed
51. Kakizaki M, Watanabe R 2017. Neuropathology. 10.1111/neup.12386. PubMed
52. Momin N, *et al.* 2022. Nat Commun. 13:109. PubMed
53. Jia P, *et al.* 2021. Nat Commun. 12:6535. PubMed
54. Price P, *et al.* 2015. J Immunol. 194:1164. PubMed
55. Kodama L, *et al.* 2020. Nat Neurosci. 1.074305556. PubMed
56. Cosentino K, *et al.* 2022. Mol Cell. 82:933. PubMed
57. Li H, *et al.* 2022. Gut Microbes. 14:2127456. PubMed
58. Ioannidis L, *et al.* 2016. J Immunol. 196: 1227 - 1238. PubMed
59. Tummers B, *et al.* 2020. Immunity. 52(6):994-1006.e8. PubMed
60. Logan T, *et al.* 2021. Cell. 184(18):4651-4668.e25. PubMed
61. Di Mitri D, *et al.* 2019. Cell Rep. 28:2156. PubMed
62. Toshiro Hirai *et al.* 2019. Immunity. 50(5):1249-1261 . PubMed
63. Buzzelli JN, *et al.* 2019. Am J Physiol Gastrointest Liver Physiol. 316:G251. PubMed
64. Mohamed E, *et al.* 2020. Immunity. 52(4):668-682.e7.. PubMed
65. Zhou T, *et al.* 2022. Sci Adv. 8:eabj9617. PubMed
66. Han Y, *et al.* 2022. Int J Biol Sci. 18:5653. PubMed
67. Xu G, *et al.* 2020. Cell Rep. 32:108170. PubMed
68. Motozono C, *et al.* 2015. J Biol Chem. 290: 18924 - 18933. PubMed
69. Qi F, *et al.* 2019. Front Microbiol. 2.140277778. PubMed
70. Ponzetta A, *et al.* 2020. Cell. 178(2):346-360.e24.. PubMed
71. Matsumura T, *et al.* 2022. Nat Commun. 13:7064. PubMed
72. Sakamoto K, *et al.* 2021. Immunity. 54:2321. PubMed
73. Wieghofer P, *et al.* 2021. EMBO J. 40:e105123. PubMed
74. Song J, *et al.* 2021. Am J Physiol Heart Circ Physiol. 320:H323. PubMed
75. Pizzurro GA, *et al.* 2021. Cancers (Basel). 13:. PubMed
76. Fujii T, *et al.* 2021. Bone Res. 9:4. PubMed
77. Richardson ET, *et al.* 2015. PLoS One. 10: 1371. PubMed
78. Wedekind MF, *et al.* 2021. iScience. 24(7):102759. PubMed
79. Laban H, *et al.* 2018. J Cell Biol. 217:1503. PubMed
80. Yousef H, *et al.* 2019. Nat Med. 25:988. PubMed
81. Pribyl M, *et al.* 2020. Mol Oncol. 2.252083333. PubMed
82. Damgaard RB *et al.* 2016. Cell. 166(5):1215-1230 . PubMed
83. Mairhofer D, *et al.* 2015. J Invest Dermatol. 135: 2785-93. PubMed
84. Skucha A, *et al.* 2018. Nat Commun. 9:1983. PubMed
85. Xia D, *et al.* 2022. Mol Neurodegener. 17:41. PubMed
86. Yin Z, *et al.* 2017. Neurobiol Aging. 10.1016/j.neurobiolaging.2017.03.021. PubMed
87. Geng X, *et al.* 2018. Aging (Albany NY). 10:1415. PubMed
88. Knox T, *et al.* 2019. Sci Rep. 9:6136. PubMed
89. Krivtsov AV, *et al.* 2020. Cancer Cell. 36(6):660-673.e11.. PubMed
90. Molgora M, *et al.* 2020. Cell. 182:886. PubMed
91. Fedele C, *et al.* 2021. J Exp Med. 218: . PubMed
92. Sakurai Y, *et al.* 2021. Pharmaceutics. 13:. PubMed
93. Heil J, *et al.* 2021. Nat Commun. 12:6963. PubMed
94. Katzmarski N, *et al.* 2021. Nat Immunol. 22:1382. PubMed
95. Zhong C, *et al.* 2021. J Virol. 95:e0092521. PubMed
96. Maas RR, *et al.* 2021. Nat Protoc. 16:4692. PubMed
97. Nakayama Y, *et al.* 2020. Proc Natl Acad Sci U S A. 117:14365. PubMed
98. Zukauskas A, *et al.* 2018. mSphere. 3:e00303. PubMed
99. Jolly A, *et al.* 2022. Cell Rep Methods. 2:100315. PubMed
100. Guan D, *et al.* 2021. Cell Death Dis. 12:431. PubMed
101. Xiao Z, *et al.* 2022. Mater Today Bio. 15:100297. PubMed
102. Sakamoto K, *et al.* 2022. STAR Protoc. 3:101052. PubMed
103. Verma M, *et al.* 2021. J Exp Med. 218:. PubMed
104. Lee GR, *et al.* 2021. JCI Insight. 6:. PubMed
105. Chetty A, *et al.* 2021. Cell Host Microbe. 29:579. PubMed
106. Reinert L, *et al.* 2016. Nat Commun. 7:13348. PubMed
107. Chen MB, *et al.* 2020. Cell Rep. 30:4418. PubMed
108. Li Z *et al.* 2018. Immunity. 49(4):640-653 . PubMed
109. Cho C *et al.* 2017. Neuron. 95(5):1056-1073 . PubMed
110. Das A, *et al.* 2020. J Bone Miner Res. 36:199. PubMed
111. Rappe JCF, *et al.* 2021. J Exp Med. 218:. PubMed
112. Caporarello N, *et al.* 2022. Nat Commun. 13:4170. PubMed
113. Bae S, *et al.* 2021. Cell Reports. 35(11):109264. PubMed

114. Harvey RE *et al.* 2017. Endocrinology. 158(7):2179-2189 . PubMed
115. Kim I *et al.* 2015. Brain and behavior. 5(12):e00403 . PubMed
116. Koda S, *et al.* 2021. Front Immunol. 12:754208. PubMed

RRID

AB_10897942 (BioLegend Cat. No. 101235)
AB_2562904 (BioLegend Cat. No. 101251)
AB_11203704 (BioLegend Cat. No. 101236)

Antigen Details

Structure	Integrin family, associates with integrin β_2 (CD18), 170 kD
Distribution	Granulocytes, monocytes/macrophages, dendritic cells, NK cells, subsets of T and B cells
Function	Adhesion, chemotaxis
Ligand/Receptor	ICAM-1 (CD54), ICAM-2 (CD102), ICAM-4 (CD242), iC3b, fibrinogen
Cell Type	B cells, Dendritic cells, Granulocytes, Macrophages, Monocytes, Neutrophils, NK cells, T cells, Tregs
Biology Area	Cell Adhesion, Cell Biology, Costimulatory Molecules, Immunology, Innate Immunity, Neuroscience, Neuroscience Cell Markers
Molecular Family	Adhesion Molecules, CD Molecules
Antigen References	1. Barclay A, *et al.* 1997. The Leukocyte Antigen FactsBook Academic Press. 2. Springer TA. 1994. *Cell* 76:301. 3. Coxon A, *et al.* 1996. *Immunity* 5:653.
Gene ID	16409 3684

Related Protocols

Cell Surface Flow Cytometry Staining Protocol

Other Formats

APC anti-mouse/human CD11b, Biotin anti-mouse/human CD11b, FITC anti-mouse/human CD11b, PE anti-mouse/human CD11b, PE/Cyanine5 anti-mouse/human CD11b, Purified anti-mouse/human CD11b, PE/Cyanine7 anti-mouse/human CD11b, Alexa Fluor® 488 anti-mouse/human CD11b, Alexa Fluor® 647 anti-mouse/human CD11b, Alexa Fluor® 700 anti-mouse/human CD11b, Pacific Blue™ anti-mouse/human CD11b, APC/Cyanine7 anti-mouse/human CD11b, PerCP/Cyanine5.5 anti-mouse/human CD11b, PerCP anti-mouse/human CD11b, Brilliant Violet 421™ anti-mouse/human CD11b, Brilliant Violet 570™ anti-mouse/human CD11b, Brilliant Violet 605™ anti-mouse/human CD11b, Brilliant Violet 650™ anti-mouse/human CD11b, Brilliant Violet 711™ anti-mouse/human CD11b, Brilliant Violet 785™ anti-mouse/human CD11b, Brilliant Violet 510™ anti-mouse/human CD11b, Ultra-LEAF™ Purified anti-mouse/human CD11b, Purified anti-mouse/human CD11b (Maxpar® Ready), Alexa Fluor® 594 anti-mouse/human CD11b, PE/Dazzle™ 594 anti-mouse/human CD11b, APC/Fire™ 750 anti-mouse/human CD11b, TotalSeq™-A0014 anti-mouse/human CD11b, Brilliant Violet 750™ anti-mouse/human CD11b, TotalSeq™-B0014 anti-mouse/human CD11b, TotalSeq™-C0014 anti-mouse/human CD11b, Spark NIR™ 685 anti-mouse/human CD11b, PE/Fire™ 640 anti-mouse/human CD11b, Spark YG™ 593 anti-mouse/human CD11b, Spark YG™ 570 anti-mouse/human CD11b, PE/Fire™ 810 anti-mouse/human CD11b, APC/Fire™ 810 anti-mouse/human CD11b Antibody, Spark Blue™ 550 anti-mouse/human CD11b, Spark UV™ 387 anti-mouse/human CD11b

Product Data



BL/6 mouse lymph nodes, fixed O/N in PLP, blocked with 10% rat serum, stained with CD11b-BV421™ (red), B220-Alexa Fluor® 647 (blue), CD14-FITC (green) in 1% BSA and 0.1% Tween-20 in PBS. Images were acquired with an automated widefield microscope (Nikon Eclipse Ti) and a CCD camera (QImaging Retiga 2000R). Emitted light was collected through 440/40, 525/50, and 700/75 nm bandpass filters. Images provided by Ann Haberman and Christine Podolski, Yale University.



C57BL/6 mouse bone marrow cells were stained with CD11b (clone M1/70) Brilliant Violet 421™ (filled histogram) or rat IgG2b, κ Brilliant Violet 421™ isotype control (open histogram). Data shown was gated on myeloid cell population.

BioLegend Inc., 8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587